These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 30453170)

  • 1. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
    Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
    Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
    Johansen A; Christensen SJ; Scheie D; Højgaard JLS; Kondziella D
    Neurology; 2019 Apr; 92(14):663-674. PubMed ID: 30850443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
    Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
    Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
    Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
    Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
    Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
    Anquetil C; Salem JE; Lebrun-Vignes B; Johnson DB; Mammen AL; Stenzel W; Léonard-Louis S; Benveniste O; Moslehi JJ; Allenbach Y
    Circulation; 2018 Aug; 138(7):743-745. PubMed ID: 30359135
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
    Kao JC; Brickshawana A; Liewluck T
    Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
    Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
    Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
    Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromuscular complications of immune checkpoint inhibitors.
    Psimaras D
    Presse Med; 2018; 47(11-12 Pt 2):e253-e259. PubMed ID: 30413332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
    Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
    Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
    Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.